# Vaderis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaderis-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.vaderis.com
- Total disclosed funding: $152M
- Latest round: Series B (Aug 11, 2026)
- Investors on record: 8

## About

Based in Basel, Switzerland, Vaderis Therapeutics AG operates as a clinical-stage biopharmaceutical company developing targeted therapies for rare vascular diseases, founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard. In August 2026, Vaderis Therapeutics AG raised USD 152 million in series B funding co-led by new investors Goldman Sachs Asset Management and TCG Crossover Management, with participation from other new investors Omega Funds, EQT Life Sciences, Perceptive Advisors, and Kalehua Capital Management. Returning investors Droia Ventures, Medicxi, and other unspecified investors also participated in the round.

## Funding rounds

- Series B, Aug 11, 2026, $152M — Goldman Sachs Asset Management, EQT Life Sciences, Omega Funds, Perceptive Advisors, Medicxi, Droia Ventures, TCG Crossover Management, Kalehua Capital Management

## Investors

- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series B
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B
- Kalehua Capital Management (https://capitalatlas.ai/funds/kalehua-capital-management) — Series B